SIRPA and glioblastoma: Blocking the CD47-SIRPα axis (e.g., with the anti-CD47 antibody Hu5F9-G4) restores the phagocytic activity of macrophages against GBM cells and can further enhance therapeutic efficacy when combined with temozolomide or immune checkpoint inhibitors [91] (Figure 3).